Introduction {#s1}
============

Hyponatremia, defined as a serum sodium concentration (\[Na^+^\]) \<136 mmol/L, is the most common electrolyte disorder encountered in clinical practice [@pone.0080451-Upadhyay1]. The most common cause of hypotonic or dilutional hyponatremia is the syndrome of inappropriate antidiuresis (SIAD). Mild hyponatremia (serum \[Na^+^\] 130--135 mmol/L) has been estimated to occur in about 15--30% of hospitalized patients, whereas the prevalence of moderate to severe hyponatremia (serum \[Na^+^\] \<130) is as high as 7% among in-hospital patients [@pone.0080451-Hoorn1].

Hyponatremia represents a serious health problem with significant associated morbidity and mortality. Acute severe hyponatremia is a medical emergency accompanied by severe neurological symptoms due to cerebral edema and can be lethal if not recognized and appropriately treated [@pone.0080451-Gill1]. The correction of hyponatremia may *per se* represent a risk and a rare but potentially lethal complication, i.e. the osmotic demyelination syndrome, may be the result of an overly rapid correction [@pone.0080451-Adrogu1]. In contrast, mild chronic hyponatremia has traditionally been considered as an asymptomatic or mildly symptomatic condition. However, recent reports indicated that even mild chronic hyponatremia can have long-term adverse effects, such as deficits in gait and attention [@pone.0080451-Renneboog1], falls [@pone.0080451-Renneboog1], bone loss and fractures [@pone.0080451-Gankam1]--[@pone.0080451-Barsony1], especially in the elderly. More recently, chronic hyponatremia has been shown to exacerbate multiple manifestation of senescence in aged rats, including senile osteoporosis, sarcopenia, cardiac fibrosis, and hypogonadism [@pone.0080451-Barsony2].

The association between hyponatremia and in-hospital mortality has been demonstrated in numerous studies. For instance, a large cohort study, which included all adult hospitalizations (n = 53236) at an academic medical center between 2000--2007, demonstrated that even mild hyponatremia was associated with increased in-hospital mortality, and that the risk of death was increased by 2.3% for each 1 mmol/L decline of serum \[Na^+^\] [@pone.0080451-Wald1].

Hyponatremia has been generally associated with an increased mortality in different conditions such as pneumonia [@pone.0080451-Zilberberg1], heart failure [@pone.0080451-Klein1], acute myocardial infarction [@pone.0080451-Waikar1], cirrhosis [@pone.0080451-Kim1], cancer [@pone.0080451-Waikar1], in the elderly [@pone.0080451-Terzian1], and in intensive care patients [@pone.0080451-Stelfox1]. However, whether hyponatremia is an independent risk factor for death or is simply associated with an underlying severe condition that is the cause of death remains to be elucidated [@pone.0080451-Adrogu1], [@pone.0080451-Chawla1]. Furthermore, there is the possibility that hyponatremia indirectly contributes to mortality by causing organ dysfunction, such as for example bone loss and fractures which are associated with significant mortality in the elderly. Recently, a meta-analysis that included 22 observational studies and randomized controlled trials published to the end of 2008, that was limited to patients with heart failure, indicated that hyponatremia is a powerful predictor of mortality in these patients regardless of ejection fraction [@pone.0080451-Rusinaru1]. However, no meta-analysis on the relationship between hyponatremia and mortality has addressed other pathological conditions to date.

The aim of this study was to perform a meta-analysis, which included the studies that compared the mortality rate in subjects with or without hyponatremia, in order to verify whether hyponatremia represents a risk factor for mortality, independently of other confounding factors.

Methods {#s2}
=======

A meta-analysis was performed including studies comparing mortality rate in subjects with or without hyponatremia. An extensive Medline, Embase, and Cochrane search was performed including the following words: hyponatremia and mortality. The search up to October 1^st^ 2012 was restricted to English-language articles and studies of human participants. The identification of relevant abstracts, the selection of studies based on the criteria described above, and the subsequent data extraction were performed independently by two of the authors (G.P., C.G.), and conflicts resolved by a third investigator (G.C). Full-text articles and meeting abstracts were included. The quality of studies was assessed using the Cochrane criteria [@pone.0080451-Higgins1].

Statistical analysis {#s2a}
--------------------

Heterogeneity was assessed using the I^2^ statistics for overall mortality rate. Considering that heterogeneity could not be excluded (I^2^ = 92.8%), relative risk of mortality between subjects with or without hyponatremia, was calculated using both a random and fixed effect model. For a more conservative approach, results of random effect models were presented. A meta-regression analysis was performed to test the effect of serum \[Na^+^\] threshold selected in the different studies on overall mortality rate levels. In addition, a linear regression analysis model, weighing each study for the number of subjects enrolled, was performed to verify the independent effect of hyponatremia on mortality after the adjustment for age, gender and diabetes mellitus as an associated morbidity. It was not possible to include other co-morbidities because there were not enough data to be collected and analyzed from the selected literature. Finally, sensitivity analyses was performed considering only larger studies (including ≥1000 subjects) or those reporting the prevalence of diabetes mellitus. In addition, mean baseline serum \[Na^+^\] in subjects who eventually died or not at follow up were meta-analyzed using a random effect model.

Relative risks (RRs) with 95% CIs were calculated using Comprehensive Meta-analysis Version 2, Biostat, (Englewood, NJ, USA). Logistic multivariate analysis was performed on SPSS (Statistical Package for the Social Sciences; Chicago, USA) for Windows 20.1.

Results {#s3}
=======

Out of 718 retrieved articles, 637 articles were excluded for different reasons. The flow of the meta-analysis is summarized in [Figure 1](#pone-0080451-g001){ref-type="fig"}, and the characteristics of the trials included in the meta-analysis are summarized in [Table 1](#pone-0080451-t001){ref-type="table"} (see references 3,11--12,16--18, 21--95). Among the 81 selected studies, 7, 13, 8, 5 studies evaluated the effect of hyponatremia on overall mortality rate in subjects with myocardial infarction, heart failure (HF), cirrhosis and pulmonary infections, respectively. In addition, another 26 studies reported data on the effect of hyponatremia on overall mortality for combined mixed diseases, which could not be grouped separately (see [Table 1](#pone-0080451-t001){ref-type="table"}). Finally, 14 studies retrospectively investigated the effect of hyponatremia on overall mortality in hospitalized series of subjects. In these studies, a major diagnosis was not specified.

![Trial flow diagram.](pone.0080451.g001){#pone-0080451-g001}
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###### Studies included in meta-analysis.

![](pone.0080451.t001){#pone-0080451-t001-1}

  Source                                                            Type of disease           Age     Male    DM    Na^+^ cut-off (mEq/L)   Patients     H       NH     Deaths H   DeathsNH   Na^+^ deaths (mEq/L)   Na^+^ survivors
  ---------------------------------------------------------- ----------------------------- --------- ------ ------ ----------------------- ---------- ------- -------- ---------- ---------- ---------------------- -----------------
  Flear et al., 1979 [@pone.0080451-Flear1]                      Myocardial infarction       57.1     78.7    NA             135              235       88      147        19         10               NA                  NA
  Goldberg et al., 2004 [@pone.0080451-Goldberg1]                Myocardial infarction        61       78    24.2            135              1047      339     708        61         44               NA                  NA
  Goldberg et al., 2006 [@pone.0080451-Goldberg2]                Myocardial infarction       59.3     80.7   22.6            136              978       108     870        26         78               NA                  NA
  Klopotowski et al., 2009 [@pone.0080451-Klopotowski1]          Myocardial infarction        NA      72.5   8.9             135              1858      96      1762       13         67               NA                  NA
  Havrànek et al., 2011 [@pone.0080451-Havrnek1]                 Myocardial infarction        64       66    33.9            135              218       72      146        25         30               NA                  NA
  Tada et al., 2011 [@pone.0080451-Tada1]                        Myocardial infarction       64.4      85    41.4            136              140       29      111        0          3                NA                  NA
  Tang et al., 2011 [@pone.0080451-Tang1]                        Myocardial infarction       63.8     6.8    2.9             135              1620      212     1408       29        103               NA                  NA
  Panciroli et al., 1990 [@pone.0080451-Panciroli1]                       HF                  67      70.2   11.8            135              161       64       97        44         39               NA                  NA
  Adewole et al., 1996 [@pone.0080451-Adewole1]                           HF                  NA       NA     NA             125               64       10       54        7          17               NA                  NA
  Chen et al., 2003 [@pone.0080451-Chen1]                                 HF                  56      63.2    NA             125              234       27      207        20         35               NA                  NA
  Villacorta et al., 2003 [@pone.0080451-VillaCorta1]                     HF                 72.5      63     NA             135              170       61      109        32         31               NA                  NA
  Gheorghiade et al., 2007 [@pone.0080451-Gheorghiade1]                   HF                  NA       NA     NA             135             40454     7882    32572      473        1042              NA                  NA
  Gheorghiade et al., 2007 [@pone.0080451-Gheorghiade2]                   HF                 56.2      NA     NA             134              430       103     327        31         52               NA                  NA
  Milo-Cotter et al, 2008 [@pone.0080451-MiloCotter1]                     HF                 74.9      51     NA             135              296       38      258        11         21               NA                  NA
  Tribouilloy et al., 2008 [@pone.0080451-Tribouilloy1]                   HF                  74      53.8   25.8            NA               662       NA       NA        NA         NA           136.7±4.9            138.4±3.6
  Rusinaru et al., 2009 [@pone.0080451-Rusinaru2]                         HF                 75.8     46.6   26.2            136              358       91      267        73        159               NA                  NA
  Barsheshet et al., 2010 [@pone.0080451-Barsheshet1]                     HF                  NA      55.3   51.7            136              2336      537     1799       54         74               NA                  NA
  DeWolfe et al., 2010 [@pone.0080451-DeWolfe1]                           HF                 54.7     62.9   34.1            135              364       48      316        8          31               NA                  NA
  Novack et al., 2010 [@pone.0080451-Novack1]                             HF                 75.6     52.2   38.3            136              8246     1755     6491       NA         NA           136.4±5.3            137.6±4.5
  Baldasseroni et al., 2011 [@pone.0080451-Baldasseroni1]                 HF                  62      74.4   11.0            135              4670      463     4207      123        433               NA                  NA
  Balling et al., 2011 [@pone.0080451-Balling1]                           HF                  68       73     NA             136              3645      602     2863      147        429               NA                  NA
  Shorr et al., 2011 [@pone.0080451-Shorr1]                               HF                 74.7     46.2    NA             135             115969    24562   91407      1372       2763              NA                  NA
  Arroyo et al., 1976 [@pone.0080451-Arroyo1]                          CIRRHOSIS              NA       NA     NA             130               55       21       34        9          6                NA                  NA
  Vila et al., 1999 [@pone.0080451-Vila1]                              CIRRHOSIS             47.3     35.2    NA             130               45       20       25        7          9                NA                  NA
  Borroni et al., 2000 [@pone.0080451-Borroni1]                        CIRRHOSIS             56.9     70.5    NA             130              191       57      134        15         12               NA                  NA
  Porcel et al,. 2002 [@pone.0080451-Porcel1]                          CIRRHOSIS             62.9     62.1    NA             130               74       54       20        37         5            123.8±5.6             129±7.7
  Ruf et al., 2005 [@pone.0080451-Ruf1]                                CIRRHOSIS              49       53     NA             130              194       34      160        NA         NA            130±6.0              136±5.0
  Hackworth et al., 2009 [@pone.0080451-Hackworth1]                    CIRRHOSIS              51       78     NA             130              213       90      123        10         10               NA                  NA
  Radha Krishna et al., 2009 [@pone.0080451-RadhaKrishna1]             CIRRHOSIS             36.3     70.2    NA             NA               121       50       71        38         16               NA                  NA
  Terg et al., 2009 [@pone.0080451-Terg1]                              CIRRHOSIS              NA       NA     NA             130               81       27       54        12         7                NA                  NA
  Jenq et al., 2010 [@pone.0080451-Jenq1]                              CIRRHOSIS              56      76.2    NA             135              126       67       59        49         33               NA                  NA
  Singhi et al., 1992 [@pone.0080451-Singhi1]                         PNEUMOPATHY            3.14      NA     NA             135              727       371     356        24         17               NA                  NA
  Sharma et al., 1995 [@pone.0080451-Sharma1]                         PNEUMOPATHY             35       51     NA             135              112       42       70        NA         NA           117.6±5.8            132.6±7.7
  El-Ebiary et al., 1997 [@pone.0080451-ElEbiary1]                    PNEUMOPATHY            59.1      75     17             136               84        9       75        6          19               NA                  NA
  Hussain et al., 2004 [@pone.0080451-Hussain1]                       PNEUMOPATHY             47       42     15             135              110       78       32        NA         NA           127.8±7.4            130.6±7.5
  Nair et al., 2007 [@pone.0080451-Nair1]                             PNEUMOPATHY            73.5      50     20             135              342       95      247        9          8                NA                  NA
  Song et al., 2008 [@pone.0080451-Song1]                             PNEUMOPATHY             NA       NA     NA             NA               929       78      851        16         62               NA                  NA
  Zilberberg et al., 2008 [@pone.0080451-Zilberberg1]                 PNEUMOPATHY            68.4     45.2    NA             135              7965      649     7316       35        293               NA                  NA
  Sunderam et al., 1983 [@pone.0080451-Sunderam1]                        AGED                 NA       0      NA             130              683       108     575        53        104               NA                  NA
  Samadi et al., 1985 [@pone.0080451-Samadi1]                      CHRONIC DIARRHEA           \<3      NA     NA             130              1330      276     1054       28         38               NA                  NA
  Cusano et al., 1990 [@pone.0080451-Cusano1]                            AIDS                36.6      89     NA             130               96       30       66        21         24               NA                  NA
  Vitting et., 1990 [@pone.0080451-Vitting1]                             AIDS                39.8      98     NA             132               48       34       14        8          2              128±2                133±1
  Erinoso et al., 1993 [@pone.0080451-Erinoso1]                      MALNUTRITION             \<5     59.3    NA             130              120       85       35        40         6                NA                  NA
  Tang et al., 1993 [@pone.0080451-Tang2]                                AIDS                34.2      NA     NA             135              210       83      127        30         25               NA                  NA
  Terzian et al., 1994 [@pone.0080451-Terzian1]                          AGED                \>65     43.4    NA             130              4123      145     3978       23        316               NA                  NA
  Chuah et al., 1996 [@pone.0080451-Chuah1]                            AMEBIASIS              NA       80     NA             135               60       23       37        15         1                NA                  NA
  Iseki et al., 1996 [@pone.0080451-Iseki1]                            DIALYSIS              50.9     56.6    NA             NA               1491      NA       NA        NA         NA           134.9±7.6            136.8±5.8
  Srivastava et al., 1998 [@pone.0080451-Srivastava1]             FULMINANT HEPATITIS         5.3     68.3    NA             125               41        3       38        3          22               NA                  NA
  Berghmans et al., 2000 [@pone.0080451-Berghmans1]                     TUMOURS               NA       NA     NA             130              3306      106     3200       21        202               NA                  NA
  Manary et al., 2000 [@pone.0080451-Manary1]                        MALNUTRITION             2.7     45.3    NA             NA                75       NA       NA        NA         NA              131                  132
  Oguche et al., 2002 [@pone.0080451-Oguche1]                           MALARIA                3       44     NA             NA                50        8       42        1          10               NA                  NA
  Agarwal et al., 2004 [@pone.0080451-Agarwal1]                   ACUTE RENAL FAILURE        \<12      70     NA             NA                54       12       42        9          19               NA                  NA
  Lee et al., 2005 [@pone.0080451-Lee1]                       BONE MARROW TRANSPLANTATION     32      58.2    NA             134              311       185     126       123         43               NA                  NA
  Sherlock et al., 2006 [@pone.0080451-Sherlock1]               SUBARACHNOID HEMORRHAGE       NA       NA     NA             136              316       179     137        19         26               NA                  NA
  Bonney et al., 2008 [@pone.0080451-Bonney1]                    LIVER TRANSPLANTATION       52.8     49.1    NA             NA                54       17       37        5          5                NA                  NA
  Forfia et al., 2008 [@pone.0080451-Forfia1]                      LUNG HYPERTENSION         55.3      17     NA             136               40       13       27        5          11               NA                  NA
  Olotu et al., 2008 [@pone.0080451-Olotu1]                    HEMOLYTIC-UREMIC SYNDROME      NA       61     NA             120               31        8       23        7          10               NA                  NA
  Hanson et al., 2009 [@pone.0080451-Hanson1]                           MALARIA               35      79.5    NA             135              168       98       70        31         36               NA                  NA
  Hsu et al., 2009 [@pone.0080451-Hsu1]                          TUMOUR LISYS SYNDROME       55.2     66.7    NA             NA                12       NA       NA        NA         NA             132±6                142±3
  Kapoor et al., 2010 [@pone.0080451-Kapoor1]                       PYELONEPHRITIS            57      15.4    NA             120               39       15       24        5          0                NA                  NA
  Dimopoulos et al., 2010 [@pone.0080451-Dimopoulos1]          CONGENITAL HEART DISEASE      36.2     48.7    NA             136              1004      156     848        35         61               NA                  NA
  Salvador et al., 2010 [@pone.0080451-Salvador1]                NECROTIZING FASCIITIS        NA       NA     22             135               67      14 53     53        6          18               NA                  NA
  Scherz et al., 2010 [@pone.0080451-Scherz1]                     PULMONARY EMBOLISM          67      40.2    NA             135             13728     2907    10821      441        866               NA                  NA
  Stelfox et al., 2010 [@pone.0080451-Stelfox2]                      HEART SURGERY           65.4     76.4   41.9            133              6727      785     5942       82        124               NA                  NA
  Hoorn et al., 2011 [@pone.0080451-Hoorn2]                              AGED                70.3     38.5    11             136              5208      399     4809      206        1567              NA                  NA
  Saifudheen et al., 2011 [@pone.0080451-Saifudheen1]           GUILLAIN BARRE SYNDROME       42       72     NA             135               50       24       26        4          0                NA                  NA
  Vaa et al., 2011 [@pone.0080451-Vaa1]                           ALCOHOLIC HEPATITIS        51.1      85     NA             NA                26       NA       NA        NA         NA              132                  136
  Tierney et al., 1986 [@pone.0080451-Tierney1]                   HOSPITALIZED SERIES        61.2      47     19             135              1514      757     757       165         60               NA                  NA
  Natkunam et al., 1991 [@pone.0080451-Natkunam1]                 HOSPITALIZED SERIES         NA       NA     NA             125              1217      202     1015       84         35               NA                  NA
  Singhi et al., 1994 [@pone.0080451-Singhi2]                     HOSPITALIZED SERIES         NA       75     NA             135              264       71      193        6          7                NA                  NA
  Miller et al., 1995 [@pone.0080451-Miller1]                     HOSPITALIZED SERIES       60--103   91.6    NA             135              119       63       56        11         12               NA                  NA
  Gill et al., 2006 [@pone.0080451-Gill1]                         HOSPITALIZED SERIES         65      47.5    NA             125              204       104     100        28         9                NA                  NA
  Asadollahi et al., 2007 [@pone.0080451-Asadollahi1]             HOSPITALIZED SERES          NA       NA     NA             134              1599      356     1243      179        377               NA                  NA
  Stelfox et al., 2008 [@pone.0080451-Stelfox1]               HOSPITALIZED SERIES SERIES     56.1     58.9    NA             133              5985      917     5068      255        799               NA                  NA
  Zilberberg et al, 2008 [@pone.0080451-Zilberberg2]              HOSPITALIZED SERIES        61.8     45.5    NA             135             198281    10899   187382     643        5621              NA                  NA
  Hampshire et al., 2009 [@pone.0080451-Hampshire1]               HOSPITALIZED SERIES         NA       NA     NA             130              6410      285     6125      208        3468              NA                  NA
  Whelan et al., 2009 [@pone.0080451-Whelan1]                     HOSPITALIZED SERIES        58.5     47.5    NA             134             14039     2795    11244      474        893               NA                  NA
  Whyte et al., 2009 [@pone.0080451-Whyte1]                       HOSPITALIZED SERIES        68.8     39.8    NA             120              226       113     113        24         7                NA                  NA
  Funk et al., 2010 [@pone.0080451-Funk1]                         HOSPITALIZED SERIES        63.2     57.6    NA             135             140952    26782   114170     4369      11074              NA                  NA
  Wald et al., 2010 [@pone.0080451-Wald1]                         HOSPITALIZED SERIES        65.3     48.2   14.9            138             34761     13274   21487      451        430               NA                  NA
  Chawla et al., 2011 [@pone.0080451-Chawla1]                     HOSPITALIZED SERIES         NA       NA     NA             135             209839    45693   164146     2787       3775              NA                  NA

H: patients with hyponatremia; NH: patients without hyponatremia; DM: diabetes mellitus; NA: not available.

The mean±SD serum \[Na^+^\] in dead or alive individuals was specified in 3 of the aforementioned studies and in a further 8 studies enrolling patients with HF (n = 2), cirrhosis (n = 1), pulmonary infection (n = 2) or mixed disease (n = 3), respectively ([Table 1](#pone-0080451-t001){ref-type="table"}).

Overall 850222 patients and 147948 hyponatremic subjects were included in the meta-analysis. Hyponatremia was defined according to varying cut-off definitions in the included studies ([Table 1](#pone-0080451-t001){ref-type="table"}). The Begg-adjusted rank correlation test, calculated on the basis of overall mortality rate for hyponatremia, suggested no major publication bias (Kendall tau 0.02; p = 0.82).

When all 81 studies were considered, hyponatremia was significantly associated with an increased risk of overall mortality (RR = 2.60\[2.31--2.93\]; p\<0.0001). Similar results were obtained when patients with specific diseases or series of hospitalized patients were analyzed separately ([Figure 2](#pone-0080451-g002){ref-type="fig"}, panels A--E). Similar to what observed for mortality rate, the Begg-adjusted rank correlation test, calculated on the basis of mean serum \[Na^+^\] between subjects who eventually died when compared to survivors, suggested no major publication bias (Kendall tau −0.145; p = 0.553). The baseline mean difference of serum \[Na^+^\] was significantly lower in subjects who eventually died when compared to survivors (130.1±5.6 *vs* 134.9±5.1 mmol/L) at follow up ([Figure 3](#pone-0080451-g003){ref-type="fig"}). Similar results were observed when studies enrolling less than 100 subjects were excluded from the analysis (mean difference in serum \[Na^+^\] between survivors *vs* dead 3.04\[1.81--4.27\], p\<0.0001). Sub-analysis for mean serum \[Na^+^\] in specific diseases was not performed due to insufficient data.

![Odds ratio for overall mortality in patients with or without (no) hyponatremia according to the presence of myocardial infarction (A), heart failure (B), cirrhosis (C), pulmonary infection (D), mixed disease (E), or in hospitalized series of subjects (F).](pone.0080451.g002){#pone-0080451-g002}

![Weighted differences (with 95% CI) of mean serum \[Na^+^\] in dead and alive patients.](pone.0080451.g003){#pone-0080451-g003}

A meta-regression analysis showed that the hyponatremia-related risk of overall mortality was inversely correlated with the serum \[Na^+^\] threshold considered for each report ([Figure 4](#pone-0080451-g004){ref-type="fig"}). Hence, the lower threshold considered, the higher the risk of mortality. The latter association was confirmed in a multiple regression model, adjusting for age, gender and diabetes mellitus (adj. r = −0.278; p\<0.0001).

![Relation between serum \[Na^+^\] cut-off definition and overall mortality risk.](pone.0080451.g004){#pone-0080451-g004}

Sensitivity analyses performed considering only larger studies (including ≥1000 subjects), those reporting the prevalence of diabetes mellitus or those with severe hyponatremia (\[Na^+^\] ≤125 mmol/l), confirmed the association between hyponatremia and mortality (RR = 2.521\[2.180--2.916\]; p\<0.0001 and 2.886\[2.228--3.737\], 10.036\[5.155--19.540\]; all p\<0.0001, respectively).

Discussion {#s4}
==========

Hyponatremia has been associated with increased in-hospital mortality [@pone.0080451-Wald1], but no published comprehensive meta-analysis that analyzed the mortality rate in subjects with or without hyponatremia had been performed to date. Very recently, the Meta-Analysis Global Group in Chronic heart failure (MAGGIC) published a meta-analysis that included 14766 patients from 22 studies that recruited patients with HF and reported death from any cause [@pone.0080451-Rusinaru1]. Patients with hyponatremia (n = 1618) had an increased risk of death (21%), compared to patients with normal serum \[Na^+^\] (16%), and the risk of death appeared to increase linearly with serum \[Na^+^\] \<140 mmol/L. Hyponatremia was an independent predictor of death either when the patients were considered as a whole, or when they were grouped based on the presence of a reduced (n = 1199) or a preserved (n = 419) ejection fraction. The MAGGIC meta-analysis was limited to patients with HF and considered studies published to the end of 2008.

Our meta-analysis included all of the English-language published studies up until October 1^st^ 2012 that compared the mortality rate in human subjects with or without hyponatremia of any degree. Eighty-one published studies were selected according to specified inclusion criteria for a total of 850222 patients, of whom 17.4% were hyponatremic. This percentage is in general agreement with epidemiological data about the prevalence of hyponatremia among hospitalized patients [@pone.0080451-Hoorn1]. Of note, hyponatremia was associated with a significantly increased risk of overall mortality when all studies were considered (RR = 2.60 \[2.31--2.93\]). A detailed analysis of cause specific mortality was not possible, because this information was not available in several studies, as also was found in the MAGGIC meta-analysis. Nevertheless, we were able to conclude that the risk of mortality was independent of factors including age, gender, and diabetes mellitus as an associated morbidity. Similarly, hyponatremia was found to be associated with an increased risk of death when the patients were analyzed separately based on different disease types or when sensitivity analysis was restricted to larger studies or those reporting the prevalence of diabetes. In particular, we were able to confirm the data of the MAGGIC meta-analysis on hyponatremic patients with HF (RR = 2.47 \[2.09--2.92\]), analyzing a greater number of patients (168971, of whom 20.4% were hyponatremic). In the MAGGIC meta-analysis, only 11% of patients were hyponatremic, which is below the prevalence of hyponatremia generally reported for hospitalized patients (15--30%) [@pone.0080451-Hoorn1]; the authors suggested that this might be due to the fact that all patients in the MAGGIC cohort were outpatients at the time of the baseline data. In contrast with the MAGGIC meta-analysis, patients with hyponatremia in our meta-analysis were neither older, nor more frequently affected by diabetes mellitus. Furthermore, we found an increased risk of mortality in hyponatremic patients with myocardial infarction (total number of patients 6096, of whom 18.3% with hyponatremia), cirrhosis (total number of patients 906, of whom 42.6% were hyponatremic), or pulmonary infections (total number of patients 10047, of whom 12% were hyponatremic). Some studies (n = 26) reported data regarding other mixed diseases or subpopulations (e.g., elderly people), which could not be grouped together. The most represented diseases among these patients (total number of patients 37864, of whom 15.1% were hyponatremic) were AIDS, malaria and malnutrition. Finally, some studies (n = 14, total number of patients 615410, of whom 16.7% were hyponatremic) were considered separately, because the effect of hyponatremia on mortality was investigated retrospectively and the diagnoses were not specified. The meta-analysis of these studies also revealed an increased risk of overall mortality.

The major finding of this meta-analysis is that across all groups of patients the relative risk of mortality in patients with hyponatremia *vs* patients without hyponatremia ranged between 2.47 and 3.34, thus indicating that this electrolyte disorder strongly predicts prognosis of all hospitalized patients. Another interesting result of our meta-analysis is that a moderate serum \[Na^+^\] reduction (i.e., 4.8 mmol/L) was associated with an increased risk of mortality, and a meta-regression analysis showed that the hyponatremia-related risk of overall mortality was inversely correlated with the serum \[Na^+^\]. Hence, the lower threshold considered, the higher the risk of mortality. This association was confirmed in a multiple regression model after adjusting for age, gender and diabetes mellitus. The linear increase of risk of death that we showed in our analysis is in agreement with the findings of the MAGGIC meta-analysis, which found a linear increase of mortality starting at serum \[Na^+^\] \<140 mmol/L. Overall, our findings indicate that even a moderate reduction of serum \[Na^+^\] is associated with an increased risk of mortality in patients affected by multiple disease types across large numbers of hospitalized patients.

Although the present meta-analysis both confirms and extends the strong association between hyponatremia and adverse outcomes such as inpatient mortality, it cannot prove a causal relation between these variables. In fact, only diabetes mellitus could be used as a possible confounder in the present study. Perhaps the major outstanding question regarding hyponatremia is whether hyponatremia contributes directly to poor outcomes or is simply a marker for severity of underlying co-morbidities, or possibly for other factors that might influence the progression of underling co-morbidities [@pone.0080451-Konstam1]. Hence, it should be recognized that potential unmeasured confounders such as other chronic diseases, in addition to diabetes mellitus, may have caused residual confounding, but the measured factors that are correlated with such confounders would have mitigated the bias. Few studies to date have attempted to address the issue of a direct effect of hyponatremia on mortality or other adverse outcomes. One oft-cited potential exception is the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) study of patients with congestive heart failure, which failed to show improvements in cardiovascular outcomes in patients with acute heart failure (AHF) treated with the vasopressin type 2 receptor (V2R) antagonist, tolvaptan, versus placebo [@pone.0080451-Konstam2]. However, that study was not powered to examine outcomes in the smaller subgroup of patients enrolled with both heart failure and hyponatremia. More recently, a significant strong positive relationship between an increase in serum sodium and decreased mortality was noted in 322 patients hospitalized for AHF and followed for 1--3 years [@pone.0080451-Madan1]. In contrast, a multicenter analysis of 2888 patients hospitalized for AHF in Korea confirmed that hyponatremia on admission was associated with a worse prognosis compared with normonatremia, but this relation persisted regardless of whether the hyponatremia improved during the hospitalization [@pone.0080451-Lee2]. However, this report was a retrospective anaylsis from a registry, not a prospective randomized trial, and the assessment of the change in serum sodium was made only once, prior to or at discharge from the hospital [@pone.0080451-Goldsmith1]. Thus, whether hyponatremia is merely a marker or also a mediator of adverse patient outcomes is still uncertain in heart failure, and has not been studied in other diseases. The current meta-analysis adds further urgency to the need to answer this question for multiple diseases, not only heart failure.

In conclusion, this study represents the first extensive and updated meta-analysis demonstrating that hyponatremia is significantly associated with an increased risk of overall mortality, and that it is a negative prognostic factor across multiple commonly observed clinical conditions, such as myocardial infarction, HF, cirrhosis and pulmonary infections. These findings might suggest the importance to correct this electrolyte disorder, even when mild, using the most appropriate strategies [@pone.0080451-Verbalis2]--[@pone.0080451-Peri2]. However, our study did not specifically address this issue and this hypothesis at present highlights the need for additional studies of clinical outcomes with effective therapies in all hyponatremic patients.
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